Long‐term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia

Documenti analoghi

• Predictors of response to emergent therapies in paediatric immune thrombocytopenia
  di: Candelaria O'Farrell, et al.
  Pubblicazione: (2025)
• Is there a role for eltrombopag drug levels in paediatric immune thrombocytopenia management?
  di: Clara Lo
  Pubblicazione: (2024)
• Short‐ and long‐term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia
  di: Boris Sorin, et al.
  Pubblicazione: (2026)
• Feasibility of plasma proteomics in patients with immune thrombocytopenia
  di: Rick Kapur
  Pubblicazione: (2024)
• Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring
  di: Shuyue Dong, et al.
  Pubblicazione: (2024)